Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Virogenomics Biodevelopment Inc (AKA: Virogenomics Inc)
Profile last edited on: 9/20/2022      CAGE: 7D7U0      UEI: SBP8W3KVM9E4

Business Identifier: Services for early stage biotech companies with drug development and grants
Year Founded
2015
First Award
2016
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

12909 Sw 68th Parkway Suite 430
Portland, OR 97223
   (503) 626-1144
   info@virogenomics.com
   virogenomics.com
Location: Single
Congr. District: 01
County: Washington

Public Profile

Virogenomics Biodevelopment Inc. works with early stage technologies to help push them out of the conceptual stage and into a commercialized product. The firm identifies technologies at major universities that have the potential for commercialization and then work in collaboration with the inventor to advance the technology to the point where it is attractive to larger investment from corporate and/or venture capitalist partners. The firm also works with other small businesses to increase the value of their technology by evaluating market opportunities, providing additional scientific experts and consultants and/or helping them to apply for and receive SBIR/STTR grants.

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
1
Conversion Rate
20.00%
Phase I Dollars
$1,392,116
Phase II Dollars
$4,441,675
Total Awarded
$5,833,791

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 2 NIH $4,666,471
Project Title: Development of DR?1-hMOG-35-55 for Treatment of DR2 Negative MS Subjects
2019 1 NIH $268,643
Project Title: Developing Novel Fibrillin Biomarkers for Aortic Disease
2019 1 NIH $299,560
Project Title: DRΑ1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
2017 1 NIH $299,186
Project Title: DRa1-MOG: a Novel Immunomodulatory Therapeutic for Stroke
2016 1 NIH $299,931
Project Title: Sensitive Single Cell Phosphocount Platform for Drug-Insensitive Cell Detection and Combination Drug Screening for Leukemia

Key People / Management

  Jeff King -- CEO

  Renee Shirley -- Coo

Company News

There are no news available.